2025 United States 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 United States 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in the United States are Pfizer Inc., Merck & Co., Sanofi, and GlaxoSmithKline (GSK). Pfizer is a leading player with its 20-valent pneumococcal conjugate vaccine, PREVNAR 20, approved by the U.S. FDA for both adults and children, offering broad protection against multiple pneumococcal serotypes. Merck recently received FDA approval for its pneumococcal 21-valent conjugate vaccine, Capvaxive, targeting invasive disease and pneumonia in adults, positioning it as a strong competitor to Pfizer’s products.
Sanofi and GSK are major vaccine producers with extensive R&D and global distribution capabilities, maintaining significant presence in the U.S. pneumococcal vaccine market through various vaccine candidates and collaborations. Sanofi collaborates with Janssen Pharmaceuticals to develop vaccines targeting related bacterial infections, while GSK continues efforts to innovate its pneumococcal vaccine portfolio. Together, these companies dominate the market by focusing on advanced vaccine formulations and strategic partnerships to address pneumococcal disease burdens across different age groups.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in the United States are Pfizer Inc., Merck & Co., Sanofi, and GlaxoSmithKline (GSK). Pfizer is a leading player with its 20-valent pneumococcal conjugate vaccine, PREVNAR 20, approved by the U.S. FDA for both adults and children, offering broad protection against multiple pneumococcal serotypes. Merck recently received FDA approval for its pneumococcal 21-valent conjugate vaccine, Capvaxive, targeting invasive disease and pneumonia in adults, positioning it as a strong competitor to Pfizer’s products.
Sanofi and GSK are major vaccine producers with extensive R&D and global distribution capabilities, maintaining significant presence in the U.S. pneumococcal vaccine market through various vaccine candidates and collaborations. Sanofi collaborates with Janssen Pharmaceuticals to develop vaccines targeting related bacterial infections, while GSK continues efforts to innovate its pneumococcal vaccine portfolio. Together, these companies dominate the market by focusing on advanced vaccine formulations and strategic partnerships to address pneumococcal disease burdens across different age groups.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
